小剂量氨茶碱联合吸入氟替卡松治疗重度稳定期慢性阻塞性肺疾病的临床效果(1)
[摘要]目的 探討小剂量氨茶碱联合吸入氟替卡松治疗重度稳定期慢性阻塞性肺疾病(COPD)的临床效果。方法 选取2016年1月～2018年4月我科收治的132例重度稳定期COPD患者作为研究对象，按照随机数字表法分为观察组(66例)与对照组(66例)。两组患者均给予氟替卡松气雾剂吸入，观察组采用小剂量氨茶碱缓释片口服，对照组采用沙丁胺醇气雾剂吸入，两组疗程均为6个月。比较两组的肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积与用力肺活量比值(FEV1/FVC)、FEV1占预计值的百分比(FEV1%)]，6 min步行距离(6MWD)、生活质量评分(SGRQ)、呼吸困难评分(mMRC)及不良反应发生情况。结果 两组患者治疗后的FVC、FEV1、FEV1/FVC、FEV1%明显高于治疗前，差异均有统计学意义(P<0.05)，观察组治疗后的FVC、FEV1、FEV1/FVC、FEV1%明显高于对照组，差异均有统计学意义(P<0.05)；两组患者治疗后6MWD明显大于治疗前，SGRQ评分和mMRC评分明显低于治疗前，差异均有统计学意义(P<0.05)，观察组治疗后的6MWD明显高于对照组，SGRQ评分和mMRC评分明显低于对照组，差异均有统计学意义(P<0.05)；两组的不良反应总发生率比较，差异无统计学意义(P>0.05)。结论 小剂量氨茶碱联合吸入氟替卡松气雾剂治疗重度稳定期COPD效果显著，能有效改善患者的肺功能，增强患者的运动耐量，提高患者的生活质量，值得临床推广和应用。
[关键词]慢性阻塞性肺疾病；氨茶碱；氟替卡松；沙丁胺醇；肺功能
[中图分类号] R563 [文献标识码] A [文章编号] 1674-4721(2019)5(c)-0090-04
Clinical effect of low dose Aminophylline combined with Fluticasone inhalation in the treatment of severe stable chronic obstructive pulmonary disease
MA Sheng-you LIANG Jian CEN Zhen-yuan ZHU Liu-li HE Hui-jun
Department of Respiratory Medicine， Pingguo People′s Hospital， Guangxi Zhuang Autonomous Region， Pingguo 531499， China
[Abstract] Objective To investigate the clinical effect of low dose Aminophylline combined with Fluticasone inhalation in the treatment of severe stable chronic obstructive pulmonary disease (COPD). Methods A total of 132 patients with severe stable COPD admitted to our department from January 2016 to April 2018 were selected as the study subjects， they were divided into observation group (66 cases) and control group (66 cases) according to the random number table method. Both groups were given Fluticasone Aerosol inhalation， the observation group was given low dose Aminophylline Sustained-Release Tablets orally， while the control group was given Salbutamol Aerosol inhalation， both groups were treated for 6 months. The pulmonary function indexes (forced vital capacity [FVC]， forced expiratory volume in the first second [FEV1]， forced expiratory volume in the first second and forced vital capacity specific value [FEV1/FVC]， percentage of FEV1 to the predicted value [FEV1%])， 6 minutes walking distance (6MWD)， quality of life score (SGRQ)， dyspnea score (mMRC) and adverse reactions were compared between the two groups. Results The FVC， FEV1， FEV1/FVC and FEV1% of the two groups after treatment were significantly higher than those before treatment， the differences were statistically significant (P<0.05). The FVC， FEV1， FEV1/FVC and FEV1% in the observation group were significantly higher than those in the control group， the differences were statistically significant (P<0.05). The 6MWD of the two groups after treatment was significantly higher than that before treatment， and the SGRQ score and mMRC score were significantly lower than those before treatment， the differences were statistically significant (P<0.05). After treatment， the 6MWD of the observation group was significantly higher than that of the control group， and the SGRQ score and mMRC score were significantly lower than those of the control group， the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Low-dose Aminophylline combined with inhalation of Fluticasone Aerosol is effective in the treatment of severe stable COPD. It can effectively improve the pulmonary function， exercise tolerance and quality of life of patients. It is worthy of clinical promotion and application., 百拇医药(马盛优 梁剑 岑贞渊)
[关键词]慢性阻塞性肺疾病；氨茶碱；氟替卡松；沙丁胺醇；肺功能
[中图分类号] R563 [文献标识码] A [文章编号] 1674-4721(2019)5(c)-0090-04
Clinical effect of low dose Aminophylline combined with Fluticasone inhalation in the treatment of severe stable chronic obstructive pulmonary disease
MA Sheng-you LIANG Jian CEN Zhen-yuan ZHU Liu-li HE Hui-jun
Department of Respiratory Medicine， Pingguo People′s Hospital， Guangxi Zhuang Autonomous Region， Pingguo 531499， China
[Abstract] Objective To investigate the clinical effect of low dose Aminophylline combined with Fluticasone inhalation in the treatment of severe stable chronic obstructive pulmonary disease (COPD). Methods A total of 132 patients with severe stable COPD admitted to our department from January 2016 to April 2018 were selected as the study subjects， they were divided into observation group (66 cases) and control group (66 cases) according to the random number table method. Both groups were given Fluticasone Aerosol inhalation， the observation group was given low dose Aminophylline Sustained-Release Tablets orally， while the control group was given Salbutamol Aerosol inhalation， both groups were treated for 6 months. The pulmonary function indexes (forced vital capacity [FVC]， forced expiratory volume in the first second [FEV1]， forced expiratory volume in the first second and forced vital capacity specific value [FEV1/FVC]， percentage of FEV1 to the predicted value [FEV1%])， 6 minutes walking distance (6MWD)， quality of life score (SGRQ)， dyspnea score (mMRC) and adverse reactions were compared between the two groups. Results The FVC， FEV1， FEV1/FVC and FEV1% of the two groups after treatment were significantly higher than those before treatment， the differences were statistically significant (P<0.05). The FVC， FEV1， FEV1/FVC and FEV1% in the observation group were significantly higher than those in the control group， the differences were statistically significant (P<0.05). The 6MWD of the two groups after treatment was significantly higher than that before treatment， and the SGRQ score and mMRC score were significantly lower than those before treatment， the differences were statistically significant (P<0.05). After treatment， the 6MWD of the observation group was significantly higher than that of the control group， and the SGRQ score and mMRC score were significantly lower than those of the control group， the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Low-dose Aminophylline combined with inhalation of Fluticasone Aerosol is effective in the treatment of severe stable COPD. It can effectively improve the pulmonary function， exercise tolerance and quality of life of patients. It is worthy of clinical promotion and application., 百拇医药(马盛优 梁剑 岑贞渊)